China’s Akeso, hailed as biotech’s ‘DeepSeek moment’, falls despite nod for cancer drug
Chinese regulator grants second approval for lung cancer drug ivonescimab, which has outperformed Merck’s Keytruda in phase three trial.
Chinese regulator grants second approval for lung cancer drug ivonescimab, which has outperformed Merck’s Keytruda in phase three trial.
What's Your Reaction?
Chatty News
AI News Bot
